Targeted Oncology Staff

Eleven months after completing therapy for diffuse large B-cell lymphoma, a 43-year-old patients reported fever, night sweats, and back pain, and a palpable lymph node was discovered in her left groin.

Justin Kline, MD, discusses what makes loncastuximab tesirine-lpyl a good bridge therapy for patients with relapsed/refractory diffuse large B-cell lymphoma to potential CAR T-cell therapy.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. The patient's case was the topic of discussion during a recent Case-Based Roundtable event.

One year after a 75-year-old patient with diffuse large B-cell lymphoma achieved remission following 6 cycles of R-CHOP, the patient relapsed but declined transplant.

During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.

After 8 months on enzalutamide, a 75-year-old patients with metastatic castration-resistant prostate cancer showed a PSA level of 60.7 ng/mL, enlargement of known pelvic lymph nodes, and progressive disease.

Looking at the challenges with CAR T-cell therapies in patients with diffuse large B-cell lymphoma Justin Kline, MD, discusses the best available therapies for patients who relapse on treatment.

A 59-year-old Asian man presented with chest pain, cough, and dyspnea. A discussion of the case was led by Shirish M. Gadgeel, MD, during a Targeted Oncology Case-Based Roundtable event.

During a live virtual event, Alicia Morgans, MD, MPH, discussed the choice of novel hormonal agents to combine with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer.

Rachel B. Salit, MD, discussed the case of a 48-year-old patient with graft-versus-host-disease.

A 51-year-old man presented with worsening fatigue on exertion and pallor, with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options in patients with chronic lymphocytic leukemia.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was later diagnosed with advanced stage non–small cell lung cancer.

During a live virtual event, Alicia Morgans, MD, MPH, discusses the appropriate usage of new genetic testing and PSMA scans in nonmetastatic castration-resistant prostate cancer.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options of BTK inhibitors in patients with chronic lymphocytic leukemia.

Tanya Dorff, MD, asks the participants of a roundtable discussion about their opinion survival data of androgen receptor–targeted therapy and treating patients with PET scan-only metastatic castration-resistant prostate cancer.

A 75-year-old patient with metastatic castration resistant prostate cancer experienced an increase hip pain and urinary frequency 12 months after external beam radiation therapy plus androgen deprivation therapy.

Twelve months following a thyroidectomy with bilateral central neck dissection and later declining systemic therapy, a 58-year-old man with medullary thyroid cancer was no longer asymptomatic.

How an oncologist treats a patients with non–small cell lung cancer wit the available treatment options is largely dependent on the patient's PD-L1 status.

The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Tanya Dorff, MD, asks the participants of a roundtable discussion which novel hormonal therapy they would choose in a patient with nonmetastatic castration-resistant prostate cancer.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.

A 51-year-old man presented with pallor and worsening fatigue on exertion and was diagnosed with multiple myeloma, standard risk, stage II.

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Tanya Dorff, MD, asks the participants of a roundtable discussion what they would recommend as next-line therapy for a patient with nonmetastatic castration-resistant prostate cancer.

During a Targeted Oncology Case-Based Roundtable event, Melissa L. Johnson, MD, director, discussed the case of 66-year-old man with non–small cell lung cancer.

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.

Tanya Dorff, MD, asks the participants of a roundtable discussion if they would order germline testing and molecular imaging in a patient with nonmetastatic castration-resistant prostate cancer.

A 77-year-old woman presented to her primary care physician with abdominal pain and fatigue.